Skip to main content

Advertisement

SpringerLink
Log in

Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Background and aim

Glioblastoma multiform (GBM); most fatal brain cancer, is incurable with molecular diversity hence identification of molecular targets that contribute to GBM tumorgenesis will be suitable for the development of diagnostic and treatment strategies. Micro-RNAs (miR); small RNA molecules, are stable in blood and play a crucial role in molecular processes in GBM. Thus it was aimed to investigate the clinical role of miR-221 and miR-222 among GBM cases as compared to healthy individuals and illustrate their role in patient’s survival.

Materials and methods

Blood samples were withdrawn from 20 GBM cases before and after treatment, a group of 20 healthy individuals were served as control. For all enrolled samples expression of miR-221 and miR-222 were detected using quantitative PCR (QPCR). Sensitivities, specificities of investigated miRs and their relation with GBM clinical characteristics and patient’s outcome were analyzed using Kaplan Meir curve.

Results

Expression of investigated miR- 221 and -222 were significantly increased in GBM cases as compared to healthy individuals (F = 12.9, at P < 0.001, F = 28.78, at P < 0.0001, respectively) and with absolute specificity for both and 90% sensitivity for miR-221 and 85% for miR-222. Among GBM patients (n = 20), mean expression level miR-221 reported significant increase with elder GBM ( > 60 years) at F = 5.7, P = 0.028, while both miR-221 and -222 showed significant difference in performance status (ECGO) at P = 0.036 and 0.007, patients with primary lesion at P = 0.001 and 0.005, surgically treatment strategy at P < 0.001 and 0.004, respectively. Patients were grouped according to their outcomes into response (complete [CR] or partial [PR]), stable disease[SD] and progressive disease [PD], miR-221 and miR-222 showed increase expression with PD and patients with worse PFS and OS were those with high miRs expression.

Conclusion

Detection of circulating miR-221 and miR-222 may be used as circulating molecular marker for diagnosis and prediction of outcome for patients with GBM. Further studies with large cohort of samples are encouraged.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Paolillo M, Boselli C, Schinelli S (2018) Glioblastoma under siege: an overview of current therapeutic strategies. Brain Sci. 8:15–20

    Article  Google Scholar 

  2. Di Carlo DT, Cagnazzo F, Benedetto N, Morganti R, Perrini P (2017) Multiple high-grade gliomas: epidemiology, management, and outcome a systematic review and meta-analysis. Neurosurg Rev. 42:1–13

    Google Scholar 

  3. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amistà P, Morandi L, Spagnolli F, Ermani M (2009) Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol. 27:1275–1279

    Article  CAS  Google Scholar 

  4. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegansheterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843–854

    Article  CAS  Google Scholar 

  5. Visani M, de Biase D, Marucci G, Cerasoli S, Nigrisoli E, Reggiani MLB, Albani F, Baruzzi A, Pession A (2014) Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III study group. Mol Oncol. 8:417–430

    Article  CAS  Google Scholar 

  6. Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, LIobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J, Califano A. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011. 147: 370–381.

    Article  CAS  Google Scholar 

  7. Riddick G, Fine HA (2011) Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol 7:439–450

    Article  CAS  Google Scholar 

  8. Wang B-C, Ma J (2015) Role of microRNA in malignant glioma. Chin Med J 128:1238–1244

    Article  CAS  Google Scholar 

  9. Zhao H, Shen J, Hodges TR, Song R, Fuller GN, Heimberger AB (2017) Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 16:59–66

    Article  Google Scholar 

  10. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M (2009) MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res. 15(16):5073–5081

    Article  CAS  Google Scholar 

  11. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 126(5):1166–1176

    CAS  PubMed  Google Scholar 

  12. Liao L, Wang J, Feng S, Lan Z (2016) The expression of MIR-221 and MIR-222 in non-small cell lung cancer and their significances. Cancer Res Clin. 28:590–594

    Google Scholar 

  13. Swellam M, ElMagdoub HM, Hassan NM, Hefny MM, Sobeih ME (2018) Potential diagnostic role of circulating MiRNAs in breast cancer implications on clinicopathological characters. Clin Biochem. 56:47–54

    Article  CAS  Google Scholar 

  14. Swellam M, Zahran RFK, Taha HAE, El-khazragy N, Abdel-Malak C (2018) Role of some circulating MiRNAs on breast cancer diagnosis. Arch Physiol Biochem. 15:25. https://doi.org/10.1080/13813455.2018.1482355

    Article  CAS  Google Scholar 

  15. Zhang C, Zhang J, Hao J, Shi Z, Wang Y, Han L, You Y, Jiang T, Wang J, Liu M, Pu P, Kang C (2012) High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Trans Med. 10:119–130

    Article  CAS  Google Scholar 

  16. Toraih EA, Aly NM, Abdallah HY, Al-Qahtani SA, Shaalan AA, Hussein MH, Fawzy MS (2017) MicroRNA–target cross-talks: key playersin glioblastoma multiforme. Tumour Biol. 39:1–22

    Article  Google Scholar 

  17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 5:649–655

    Article  CAS  Google Scholar 

  18. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta DeltaC(T)) method. Methods 25(4):402–408

    Article  CAS  Google Scholar 

  19. Zweig MH, Campbell G (1993) Receiver operating characteristics (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 39:561–577

    CAS  PubMed  Google Scholar 

  20. Huang SW, Ali ND, Zhong L, Shi J (2018) MicroRNAs as biomarkers for human glioblastoma: progress and potential. Acta Pharmacol Sinica 39:1405–1413

    Article  CAS  Google Scholar 

  21. Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, Wang B, Wang G, Jia Z, Pu P, Zhang W, Kang C (2010) Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Investig. 90:144–155

    Article  CAS  Google Scholar 

  22. Biau J, Dalloz P, Durando X, Hager MO, Ouédraogo ZG, Khalil T, Lemaire JJ, Chautard E, Varrelle P (2015) Elderly patients with glioblastoma: state of the art. Cancer Bull. 102(3):277–286

    Article  Google Scholar 

  23. Smrdel U, Vidmar MS, Smrdel A (2018) Glioblastoma in patients over 70 years of age. Radiol Oncol. 52(2):167–172

    Article  CAS  Google Scholar 

  24. Yang W, Warrington N, Taylor S, Whitmire P, Carrasco E, Singleton K, Wu N, Lathia J, Berens M, Kim A, Barnholtz-Sloan J, Kristin R, Swanson K, Luo J, Rubin J (2019) Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Sci. Transl. Med. 11(473):eaao5253. https://doi.org/10.1126/scitranslmed.aao5253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Cayuelaa N, Simo M, Majos C, Rifa-Ros X, Gallego J, Erez-Larraya P, Ripolles P, Vidala N, Miro J, Gild F, Gil-Gila M, Plansa G, Grausd F, Brunaa J (2017) Seizure-susceptible brain regions in glioblastoma: identification of patients at risk. Eur J Neurol. https://doi.org/10.1111/ene.13518

    Article  Google Scholar 

  26. Zhu P, Du X, Lu G, Zhu JJ (2017) Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab a population-based study. Oncotarget. 8(27):44015–44031

    Article  Google Scholar 

Download references

Acknowledgements

The instruments listed in the current study were purchased through a grant from Science and Technology Development Fund (STDF) through Capacity Building Grant Fund (CBG) [No. 4940].

Author information

Authors and Affiliations

  1. Genetic Engineering and Biotechnology Research Division, Biochemistry Department, National Research Centre, Dokki, Giza, Egypt

    Menha Swellam

  2. High Throughput Molecular and Genetic Laboratory, Center for Excellences for Advanced Sciences, National Research Centre, El-Bohouth Street, Dokki, Giza, 12622, Egypt

    Menha Swellam

  3. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Lobna Ezz El Arab

  4. Chemistry Department, Faculty of Science, Damietta University, New Damietta, Egypt

    Amr S. Al-Posttany & Samy B. Said

Authors
  1. Menha Swellam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lobna Ezz El Arab
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amr S. Al-Posttany
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samy B. Said
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Menha Swellam.

Ethics declarations

Conflict of interest

Authors report no conflicts of interest in this work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Swellam, M., Ezz El Arab, L., Al-Posttany, A.S. et al. Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform. J Neurooncol 144, 545–551 (2019). https://doi.org/10.1007/s11060-019-03256-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-019-03256-2

Keywords

Search

Navigation